Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study.
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
Background: Antibacterials may be initiated out of concern for bacterial coinfection in coronavirus disease 2019 (COVID-19). We determined prevalence and predictors of empiric antibacterial therapy and community-onset bacterial coinfections in hospitalized patients with COVID-19. Methods: A randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020 and 6/18/2020. Data were collected on early (within 2 days of hospitalization) empiric antibacterial therapy and community-onset bacterial coinfections (positive microbiologic test ≤3 days). Poisson generalized estimating equation models were used to assess predictors. Results: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric antibacterial therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric antibacterial use varied from 27% to 84%. Patients were more likely to receive early empiric antibacterial therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00–1.08] per 10 years); had a lower body mass index (ARR: 0.99 [0.99–1.00] per kg/m2), more severe illness (eg, severe sepsis; ARR: 1.16 [1.07–1.27]), a lobar infiltrate (ARR: 1.21 [1.04–1.42]); or were admitted to a for-profit hospital (ARR: 1.30 [1.15–1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs April [85.2%, 628/737], P < .001) and empiric antibacterial use (ARR: 0.71 [0.63–0.81] April vs March) decreased. Conclusions: The prevalence of confirmed community-onset bacterial coinfections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a discharge diagnosis of COVID-19, because COVID-19 patients were frequently prescribed unnecessary antibiotics and this could distort trends in broad-spectrum antimicrobial utilization”
From Trends in empiric broad-Spectrum antibiotic use for suspected community-onset Sepsis in US hospitals (2024) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288 · cited 1×
“Azithromycin in the absence of other antibacterial treatment was not included as many MI-COVID19 hospitals recommended its use as COVID19–specific therapy [18].”
MethodRetractedClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415 · cited 1×
“Specifically, patients with COVID-19 are often started empirically on antibacterials when first hospitalized [2, 11].”
BackgroundWu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664 · cited 1×
“15 decompensation.(24) Further studies are needed to aid clinicians in distinguishing the two.”
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657 · cited 2×
“Includes patients who received antibacterials recommended for empiric communityacquired pneumonia (CAP) treatment in 2019 CAP guidelines [17] (ie, ampicillin/sulbactam, cefotaxime, ceftriaxone, moxifloxacin, levofloxacin, ceftaroline) and did not receive empiric anti-MRSA or anti-pseudomonal coverage.”
BackgroundSelf-citationRawson, T. M., Moore, L. S. P., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., Satta, G., Cooke, G., & Holmes, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa530 · Cited by 1,662 · cited 2×
“Similar to other studies [4, 9, 11, 20], we found that patients hospitalized with COVID-19 were often treated with early empiric antibacterials.”
BackgroundResultCo-infections in people with COVID-19: a systematic review and meta-analysis.
Lansbury, L., Lim, B., Baskaran, V., & Lim, W. S. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.046 · Cited by 1,619 · cited 1×
“However, patients with COVID-19 may be at risk for concomitant bacterial infections that would require antibacterial treatment.(4) Data on bacterial co-infections are sparse and variable, with reports of co-infections occurring in 3-30% of patients with COVID-19.”
BackgroundLangford, B. J., So, M., Raybardhan, S., Leung, V., Westwood, D., MacFadden, D. R., Soucy, J.-P. R., & Daneman, N. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.016 · Cited by 1,569 · cited 1×
“Similar to other studies [4, 9, 11, 20], we found that patients hospitalized with COVID-19 were often treated with early empiric antibacterials.”
ResultHughes, S., Troise, O., Donaldson, H., Mughal, N., & Moore, L. S. P. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.06.025 · Cited by 642 · cited 1×
“1% later during hospitalization) [7], and a study in New York, which identified 3.”
BackgroundCo-infection with respiratory pathogens among COVID-2019 cases
Zhu, X., Ge, Y., Wu, T., Zhao, K., Chen, Y., Wu, B., Zhu, F., Zhu, B., & Cui, L. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198005 · Cited by 607 · cited 1×
“Other studies with systematic sampling have found bacterial coinfections in up to 30% of patients with COVID-19; though it is unclear the clinical significance as only 4% were severely or critically ill.(6)”
BackgroundTocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., Zhou, N., Petty, L. A., Baang, J. H., Dillman, N. O., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa954 · Cited by 497 · cited 1×
“It is likely that, for some patients, bacterial coinfections develop later in hospitalization [25].”
Self-citationMaking Profits And Providing Care: Comparing Nonprofit, For-Profit, And Government Hospitals
Horwitz, J. R. (2005) · Health Affairs · doi:10.1377/hlthaff.24.3.790 · Cited by 321 · cited 1×
“Other studies have found for-profit hospitals to have more variable quality of care [21, 22]; however, this has not been seen previously with hospitalized patients with pneumonia in HMS hospitals [15].”
ResultNori, P., Cowman, K., Chen, V., Bartash, R., Szymczak, W., Madaline, T., Punjabi Katiyar, C., Jain, R., Aldrich, M., Weston, G., et al. (2021) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2020.368 · Cited by 290 · cited 1×
“6% of hospitalized patients with COVID-19 who had bacterial or fungal coinfections [8].”
BackgroundCoronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?
Clancy, C. J., & Nguyen, M. H. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa524 · Cited by 274
Vaughn, V. M., Flanders, S. A., Snyder, A., Conlon, A., Rogers, M. A. M., Malani, A. N., McLaughlin, E., Bloemers, S., Srinivasan, A., Nagel, J., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3640 · Cited by 247 · cited 4×
“9% in our prior study of patients hospitalized with pneumonia in HMS hospitals [15].”
BackgroundMethodResultSelf-citationImproving sepsis treatment by embracing diagnostic uncertainty.
Prescott, H. C., & Iwashyna, T. J. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201809-646ps · Cited by 110 · cited 1×
“Finally, we need better training and understanding of how to incorporate imperfect tests and diagnostic uncertainty into decision making [27].”
BackgroundSelf-citationInvolving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck
Stevens, M., Patel, P., & Nori, P. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.69 · Cited by 108 · cited 1×
“antibacterial use can be reduced even during pandemics; for example, by fast-moving, responsive, and well-supported antibiotic stewardship programs.(23)”
BackgroundSelf-citationCommunity-acquired Coinfection in Coronavirus Disease 2019: A Retrospective Observational Experience
Lehmann, C. J., Pho, M. T., PITRAK, D. L., Ridgway, J. P., & Pettit, N. N. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa902 · Cited by 86
Vaughn, V. M., Gandhi, T. N., Conlon, A., Chopra, V., Malani, A. N., & Flanders, S. A. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1102 · Cited by 69
Self-citationCritical Illness in Patients With COVID-19: Mounting an Effective Clinical and Research Response
Cook, D. J., Marshall, J. C., & Fowler, R. (2020) · JAMA · doi:10.1001/jama.2020.5775 · Cited by 46
Ethical Issues in For-Profit Health Care
Gray, B. H. (1986) · Cited by 29
Yee, C., Suarthana, E., Dendukuri, N., Nicolau, I. A., Semret, M., & Frenette, C. H. (2016) · American Journal of Infection Control · doi:10.1016/j.ajic.2016.04.221 · Cited by 24 · cited 1×
“Notably, antibacterials were stopped after COVID-19 tests returned positive at higher rates than with other viral pneumonias [26].”
BackgroundBrock, D. W., & Buchanan, A. (1987) · The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine · doi:10.1093/jmp/12.1.1 · Cited by 22
A Deeper Dive Into Antibiotic Stewardship Needs: A Multihospital Survey
Vaughn, V. M., Petty, L. A., Flanders, S. A., Malani, A. N., Patel, T. S., Bernstein, S. J., Hsaiky, L. M., Thyagarajan, R. V., Osterholzer, D., McLaughlin, E. S., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa007 · Cited by 19 · cited 6×
“Participating CQIs include the following: Hospital Medicine Safety (HMS) Consortium, Michigan Bariatric Surgery Collaborative (MBSC), Michigan Surgical Quality Collaborative (MSQC), Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI), Michigan Value Collaborative (MVC), Michigan Emergency Departme…”
MethodSelf-citationNori, P., Patel, P., & Stevens, M. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.1393 · Cited by 7 · cited 1×
“6% of hospitalized patients with COVID-19 who had bacterial or fungal coinfections [8].”
BackgroundSelf-citation
Research works printed but not linked: 1
- Vaughn VM, Gandhi T, Conlon A, Chopra V, Malani AN, Flanders SA. The association of antibiotic stewardship with fluoroquinolone prescribing in Michigan hospitals: a multi-hospital cohort study. Clin Infect Dis 2019; 69: 1269– 77. 30759198 PMC6763628 · DOI
Cited by
Yeoh, Y. K., Zuo, T., Lui, G. C.-Y., Zhang, F., Liu, Q., Li, A. Y., Chung, A. C., Cheung, C. P., Tso, E. Y., Fung, K. S., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323020 · Cited by 1,317
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., Sigfrid, L., Harrison, E. M., Docherty, A. B., de Silva, T. I., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00090-2 · Cited by 327
The role of co-infections and secondary infections in patients with COVID-19
Feldman, C., & Anderson, R. (2021) · Pneumonia · doi:10.1186/s41479-021-00083-w · Cited by 319
Bacterial Coinfections in Coronavirus Disease 2019
Westblade, L. F., Simon, M. S., & Satlin, M. J. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.018 · Cited by 216
Metadata
- Authors
- Vaughn, V. M., Gandhi, T. N., Petty, L. A., Patel, P. K., Prescott, H. C., Malani, A. N., Ratz, D., McLaughlin, E., Chopra, V., & Flanders, S. A.
- Affiliations
- University of Michigan (US)
- Trinity Health Michigan (US)
- Corresponding author
- Vaughn, Valerie M
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-21
- Volume
- 72
- Issue
- 10
- Pages
- e533-e541
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC7499526
- OpenAlex
- W3081368778
- Cited by
- 396
- References
- 28
- Citations by year
- 2026: 19 · 2025: 15 · 2024: 42 · 2023: 90 · 2022: 111 · 2021: 103 · 2020: 14
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Agency for Healthcare Research and Quality
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Keywords
- COVID-19 pandemic, SARS-CoV-2, bacterial co-infection, hospitalized patients, test turnaround time, hospital variation, for-profit hospitals, body mass index, severe sepsis, antibiotic prescribing, COVID-19 testing capacity, Michigan hospitals, Michigan
- MeSH terms
- COVID-19, SARS-CoV-2, Anti-Bacterial Agents, Hospitalization, Hospitals, Humans, Michigan, Cohort Studies, Coinfection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.